Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?
a. Nivolumab (monotherapy)
b. Nivolumab AND Ipilimumab (combination)
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma?
a. Nivolumab (monotherapy)
b. Nivolumab + Ipilimumab
c. Nivolumab + Cabozantinib
d. Avelumab + Axitinib
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of upper gastrointestinal cancer (oesophageal cancer, gastric cancer and gastro-oesophageal junction cancer)?
a. Nivolumab
b. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
Q4. Does your trust participate in any clinical trials for the treatment of Melanoma? If so, please provide the name of each active trial, and the number of patients taking part.
Q5. Does your trust participate in any clinical trials for the treatment of Renal Cell Carcinoma? If so, please provide the name of each active trial, and the number of patients taking part.
